96 results about "All-trans-Tretinoin" patented technology

Disclosed are methods for generating a neuron expressing Hoxc8 transcription factor or a caudal motor neuron comprising culturing an embryonic stem cell in a composition which is essentially free of retinoids and comprises an isotonic salt solution, so as to generate the neuron which expresses Hoxc8 transcription factor or the caudal motor neuron. Disclosed are also methods for generating a caudal brachial motor neuron, a thoracic motor neuron, or a lumbar motor neuron from an embryonic stem cell in a composition essentially free of retinoids and comprising ADFNK medium, an amount of FGF-2, or Gdf11 respectively. Disclosed are also methods of transplanting a motor neuron into a subject comprising generating the motor neuron and transplanting the motor neuron into the subject. Disclosed is also a population of motor neuron cells enriched for motor neuron cells expressing Foxp1 and expressing a gene associated with Spinal Muscular Atrophy (SMA) or Amyotrophic Lateral Sclerosis (ALS).

The invention provides an inducing method for differentiating umbilical cord mesenchymal stem cells (UC-MSCs) into neural stem cells. The inducing method comprises the following steps: carrying out separation and primary culture of UC-MSCs, subculture and amplification of UC-MSCs, induction in vitro of UC-MSC to be transformed into neural stem cells, and differentiation culture of neural stem cells and detection by an immumofluorescence method. The inducing method provided by the invention uses all-transretinoic acid combined with alkaline fibroblast growth factors (bFGF) and epidermal growth factor (EGF) to induce the UC-MSCs to be transformed into neural stem cells, wherein the UC-MSCs still have stronger activity after repeated passage by division growth. The transretinoic acid is combined with cytokines to induce the UC-MSCs to be converted into the neural stem cells, so that the mesenchymal cells are differentiated into non mesenchymal cells cross germinal layer, and the mesenchymal cells probability become more ideal seed cells in the future clinical application.

The invention discloses an induction culture medium which comprises a solvent DMEM (dulbecco's modified eagle medium)-high sugar culture medium, platelets, all-trans vitamin A acid, activin A, glicetin I, a fibroblast growth factor, beta cytosine, an insuline-like growth factor, nicotinamide, polypeptide, pentagastrin and mercaptoethanol. Physical oscillation and collagenase / pancreatin dual digestion are performed to efficiently separate fat mesenchymal stem cells from human fat tissues. The fat mesenchymal stem cells are cultured for proliferation and subcultivation, and the induction culture medium is utilized to induce the fat mesenchymal stem cells to become insulin secreting cells, so that more than 40% of the fat stem cells are induced to differentiate into the insulin secreting cells.

The invention provides a method for transforming 11-cis-tretinoin into all-trans tretinoin, which is characterized by using a palladium nitrate composite catalyst. The invention also provides a method for synthesizing the all-trans tretinoin, which comprises the following steps of: using compounds (II) and (III) as raw materials to perform WITTIG reaction under the action of alkali so as to obtain a mixture of all-trans retinoic acid ester and 11-cis-retinoic acid ester; performing hydrolysis and acidification to obtain a mixture of the all-trans tretinoin and an isomer 11-cis-tretinoin; and transforming the isomer to obtain the target product namely the all-trans tretinoin. The method can be finished by two steps and has the advantages of complete reaction, high yield, less isomer content in the finished product and low cost, and is suitable for industrial production.

The invention discloses a composite of all-trans-retinoic acid and liposome and application thereof. The composite of all-trans-retinoic acid and liposome consists of the liposome and the all-trans-retinoic acid encapsulated in the liposome. The composite is prepared by a method comprising: 1) dissolving lipid materials and the all-trans-retinoic acid to prepare a mixture of a lipid membrane and the all-trans-retinoic acid; 2) hydrating the mixture of the liquid membrane and the all-trans-retinoic acid to prepare a hydration product; and 3) performing ultrasonic on the hydration product to prepare the composite of the all-trans-retinoic acid and the liposome. Experiments of the invention prove that the composite of the all-trans-retinoic acid and the liposome can be used for inhibiting the reproduction of tumor cells, and the combined application of the composite of the all-trans-retinoic acid and the liposome and Vinorelbine invisibile liposome produces the strongest inhibitory effect on the recrudesce of tumors.

The present invention relates generally to chemical compounds and substances which are effective against Hepatitis C virus (HCV) infections. Moreover, the present invention relates to compositions comprising said compounds and / or substances, to methods for preventing HCV infections as well use of the compounds and / or substances for the preparation of compositions useful for the prophylaxis and / or treatment of HCV infections. Useful compounds and substances according to the invention are selenium, selenium salts, Vitamin D3 and retinoids, like all trans retinoic acid and salts thereof, C1-C alkyl amides of all trans retinoic acid and salts thereof, C1-C10 alkyl esters of all trans retinoic acid and salts thereof, 9-cis retinoic acid and salts thereof, C1-C10 alkyl amides of 9-cis retinoic acid and salts thereof, C1-C10 alkyl esters of 9-cis retinoic acid and salts thereof, (E)-4-[2(5,6,7,8-tetrahydro-5,5,8,8-tetra methyl-2-naphthalenyl-1-propenyl)benzoic acid (TTNPB), (4-[5,6,7,8-tetrahydro5,5,8,8-tetramethyl-2-naphthalenyl)carboxamido]benzoic acid (AM-580), N-(4-hydroxyphenyl)retinamide (4-HPR), and 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphthalene carboxylic acid (AHPN).

The invention belongs to the field of biomedicine, and relates to a method for differentiation of embryonic stem cells into nerve cells through in vitro induction, especially to a method for induction of Olig2<+>-GFP<+>-mES nerve cell differentiation through a purine derivative Purmorphamine, and uses thereof. According to the present invention, an embryoid body mediated nerve induction method is adopted, Olig2-GFP<+>-mES is adopted as a cell model, a purine derivative Purmorphamine and all-trans retinoic acid are combined to carry out directed induction on the Olig2-GFP<+>-mES cells to obtain spinal motor neurons and oligodendrocyte progenitor cells through differentiation; experiment results show that the Purmorphamine can be used as a substitute of SHH, can effectively induce Olig2<+>-GFP<+>-mES differentiation to obtain high purity and function spinal motor neurons and oligodendroglial cells, and can cause expression changes of related genes; and transplant experiment results show that the induced nerve cells can promote partial function and morphology restoration after rat spinal cord injury, and have effects of spinal cord injury regeneration promotion and function reconstruction.

The invention provides an adult regulatory T cell in-vitro amplification culture medium and an application method thereof. The adult regulatory T cell in-vitro amplification culture medium comprises transform growth factor-beta (1-4 ng / ml), bone morphogenesis protein 4 (8-12 ng / ml), recombinant human interleukin-2 (300-500U / ml), rapamycin (80-100nM / ml), al-trans vitamin A acid (1-4 uM / mL), 4-hydroxyethylpiperazinoethylsulfonic acid (20-30mM / ml), L-glutamine (2mM / ml), 2-mercaptoethanol (40-50uM / ml), 5% human AB type serum, CD3CD28 magnetic bead, penicillin (50U / ml) and streptomycin (50ug / ml). When being used for performing amplification culture and induced differentiation on regulatory T cells, the culture medium can shorten the amplification and differentiation time of the regulatory T cells, and can obtain the high-purity Foxp3CD4+CD25+CD127-regulatory T cells. Therefore, the regulatory T cells can be used in the aspect of clinical treatment of anti-transplantation immunity rejection, autoimmune disease, allergic disease and the like to perform a novel clinical cell therapy.

The invention relates to non-spherical drug-loaded particles and a controlled release preparation of a lactyl polymer and preparation methods thereof. The non-spherical particles of polylactic-co-glycolic acid (PLGA) are prepared by using an emulsion-solvent volatilization method assisted by small molecule materials. The PLGA is used as raw material coated with at least one of the following hydrophobic drugs: all-trans retinoic acid, paclitaxel, epirubicin, camptothecin or roxithromycin, wherein the mass ratio of the hydrophobic drug to a lactyl polymer high polymer material is 1:4-40. The drug-loaded particles of the all-trans retinoic acid are prepared and subjected to in vitro drug release evaluation. The results show that the preparation method has the advantages of simple preparation process, good reproducibility, significantly increased drug loading amount and encapsulation efficiency relative to spherical particles, very good controlled-release effect, no hemolysis initiation and safety use. The novel carrier and preparation have a potential industrial production value in the field of long-circulating controlled release of the hydrophobic drugs.

The invention provides a method for inducing differentiating human amniotic mesenchymal stem cells (hAMSCs) to differentiate into neuron-like cells by adopting all-trans retinoic acids, a basic fibroblast growth factor (bFGF) and an epidermal growth factor (EGF). The method comprises the following steps of: separating the hAMSCs, carrying out primary culture of the hAMSCs, subculturing and amplifying the hAMSCs, detecting hAMSCs immunophenotyping, inducing the hAMSCs to differentiate into the neuron-like cells and carrying out cellular immunity fluorescence staining. According to the inducing method provided by the invention, umbilical cord mesenchymal stem cells are induced to differentiate into neutral stem cells by using the all-trans retinoic acids in combination of the bFGF and the EGF; the neural stem cells not only have the typical morphology of nerve cells, but also express neuron marker antigen neuron-specific emolase and astrocyte marker antigen glial fibrillary acidic proteins; and the capability of a mesenchymal cell trans-germinal layer differentiating into non mesenchymal cells is realized so that the mesenchymal cells are likely to turn into more ideal seed cells for clinical application in further.

The invention discloses a quantitative RT-PCR primer and probe and agent box of PML-RARa fusing gene mRNA fluorescence with BCR-ABL fusing gene primer and probe sequence as SEQ ID NO1-4 and internal reference gene primer and probe sequence as SEQ ID NO5-7, wherein the agent box contains cell cracking liquid, water, RT-PCR reacting liquid, internal reference G6PDHRT-PCR reacting liquid, BCR-ABL fusing gene detecting probe, G6PDH internal reference gene testing probe, composite enzyme, standard material and comparing material; the invention measures the expressive level of L-pattern, S-pattern and V-pattern mRNA simultaneously, rapidly and precisely, which improves inducing buffer rate and lessens early bleeding death.

The invention discloses an all-trans retinoic acid-camptothecin anticancer drug conjugate as well as a preparation method and application thereof. The structural formula of the all-trans retinoic acid-camptothecin anticancer drug conjugate is shown in a formula (I), (II), (III), (IV), (V) or (VI). The all-trans retinoic acid-camptothecin anticancer drug conjugate has good solubility in Tween, polyoxyethylene castor oil, a Poly(ethylene adipate)-polylactic acid copolymer and a Poly(ethylene adipate)-poly (lactic acid-glycollic acid) copolymer, can be self assembled into nanometer grains in water, can be directly injected or taken orally or processed into other dosage forms. According to the all-trans retinoic acid-camptothecin anticancer drug conjugate disclosed by the invention, as all-trans retinoic acid and SN-38 or camptothecin take synergistic effect, compared with a conjugate only containing one of irinotecan, SN-38 and all-trans retinoic acid, the all-trans retinoic acid-camptothecin anticancer drug conjugate has good tumor suppression effect.

The invention relates to a medicine conveying system formed by ligand polypeptide PH1 and an application thereof. The medicine conveying system comprises a ligand polypeptide PH1, a medicine carrying system and at least one active substance, wherein the polypeptide PH1 is connected on the surface of the medicine carrying system. The invention also relates to the application of the ligand polypeptide PH1 in preparing a medicine capable of specifically binding tumor-related macrophage. Discovered and proved by long-time test, the polypeptide PH1 can well target tumor-related cells, induce the differentiation of the tumor-related cells and suppress the tumor growth; the composite of PH1 polypeptide lipidosome can well target the tumor-related macrophage and can be applied to target conveying of the tumor-related macrophage of small-molecular medicines and gene medicines. The medicine conveying system has the advantages that the transretinoic acid polypeptide lipidosome can induce the differentiation of the tumor-related macrophage and suppress the tumor growth effectively, and can be applied to inhibiting proliferation of the tumor cells and the neoplasm recurrence so as to have great medical practicability.

The invention provides a granular type adjuvant as well as a preparation method and application thereof. The granular type adjuvant is prepared from a biocompatible wall material, biocompatible greaseand all-trans retinoic acid, wherein an inner core formed by the biocompatible grease is covered in a shell formed by the biocompatible wall material; the all-trans retinoic acid is coated in the inner core. According to the granular type adjuvant provided by the invention, compared with single activation of an existing method, systemic immunization and mucosal immunization are activated throughan injection immunization method, and a dual activation effect of the systemic immunization and the mucosal immunization is realized; antigens and hydrophobic immunoregulation substances ATRA are commonly loaded, delivered and released at the same time.

The invention discloses culture solution for inducing mesenchymal stem cells to differentiate into glomerular mesangial cells and an inducing method. The culture solution comprises a human platelet-derived growth factor-BB, all-trans-retinoic acid, collagen-IV and a basic medium, wherein the basic medium is a low-sugar DMEM (Dulbecco's modified eagle medium) containing 2% of horse serum and 5ng / ml of bFGF (basic fibroblast growth factor). The inducing method includes the steps: preparing the inducing culture solution; preparing the mesenchymal stem cells; coating a culture plate by the collagen-IV with the concentration of 5ug / cm<2>; inoculating the mesenchymal stem cells with the cell density of 5*103 / cm<2> into the coated culture plate and adding the inducing culture solution; changing the solution once every three days and performing inducing culture for seven days. The mesenchymal stem cells are jointly induced to differentiate into the glomerular mesangial cells by the aid of the human platelet-derived growth factor-BB, the all-trans-retinoic acid and the collagen-IV, inducing period is short, inducing efficiency is high, the glomerular mesangial cells formed by differentiation are high in functional activity, and transplantation therapy of kidney diseases such as kidney failure is facilitated.

A method of the large-scale preparation of the dimensional formyl phenol amine compound provides a method of the large-scale preparation of the dimensional formyl phenol amine compound; the method is simple, low in cost, high in collection rate, and simple in the post processing. In the method, the wholly inversed dimensional formic acid is used as the starting material to react with the chlorination agent to produce the acyl chloride; then the acyl chloride reacts with the organic alkali to form the salt; the acyl ammonium salt and the substituted amino phenol do the amidation reaction to produce the dimensional formyl phenol amine compound. The substituted amino phenol is the compound as shown in the formula (I), wherein R is H, NO2, CO2R1, OR1, NHCOR1, SO2R1; R1 is the alkyl of C1 to C4. The chlorination agent is the dichloro sulfoxide, phosphorus trichloride, phosphorus oxychloride and so on; the organic alkali is the triethylamine, pyridine and the derivative, and so on. The molar ration between the used chlorination agent and the wholly inversed dimensional formic acid is 1.0 to 5.0; the molar ration between the used substituted amino phenol and the wholly inversed dimensional formic acid is 1.0 to 10.0.

The invention provides an application of Prx I / II in screening of medicaments for treating leukemia, wherein the Prx I / II is used as a medicament target to screen medicaments which inhibits PRX I / II enzyme activity and thus has a differentiation effect on leukemia cells. According to the invention, screened adenanthin and derivatives thereof are used for realizing the differentiation effect for acute promyelocytic leukemia, thereby showing significant effects for treating all-trans retinoic acid sensitive and all-trans retinoic acid resistant leukemia. The adenanthin is safe, low in toxicity and strong in pharmacological effect, and indicates good medicinal prospects. The adenanthin active substance provided by the invention has characteristics of easy absorption, good stability, etc., and is relatively suitable for developing as novel medicaments, foods, health products or dietary additives.

The present invention is method of inducing differentiation of human human amnion mesenchyme stem cell to nerve cell. The method is to culture human human amnion mesenchyme stem cell in DMEM / F12 culture medium containing all transcofiguration vitamin A acid, basic fibroblast growth factor and ox embryo blood serum. Through the induction of the method, human human amnion mesenchyme stem cell may be differentiated extracorporeally into neure cell. The nerve cell of the present invention and composition containing the nerve cell may be used widely in treating neurogenic diseases.

The invention relates to a pharmaceutical composition containing arctigenin and an application of the pharmaceutical composition in preparing medicine for treating cancer, especially an application of the pharmaceutical composition in preparing medicine for treating leukemia. The pharmaceutical composition of the invention comprises the active components arctigenin and all-trans retinoic acid. Preferably, according to an amount of substance, in the pharmaceutical composition of the invention, the mol ratio of arctigenin to all-trans retinoic acid is 1:0.01-100. In the pharmaceutical composition, the combination of the active components arctigenin and all-trans retinoic acid has synergetic effect for anti-leukemia.

The invention belongs to the field of cytobiology and relates to a method for efficiently inducing umbilical cord mesenchymal stem cells to differentiate into Schwann-like cells. The method comprises the following steps of: (1) culturing the umbilical cord mesenchymal stem cells to a sub-fusion state, discarding the old culture solution, and adding culture solution comprising 1 mM of beta-mercaptoethanol to induce overnight; (2) discarding the induction solution, washing with a Dulbecco modified eagle medium (DMEM), and adding all-trans retinoic acid to induce for 60 to 84 hours; and (3) discarding the induction solution, washing with the DMEM, adding composition induction solution comprising 5 to 6 ng / ml of platelet-derived growth factors, 9 to 10 ng / ml of alkaline desmocyte growth factors, 13 to 15 uM of Forskolin and 250 to 260 ng / ml of gliocyte growth factors or 200 to 210 ng / ml of nerve growth factors to induce for 10 to 16 days, and change the solution for one time every other 72 hours. By the method, the inductivity can reach over 90 percent.

An N-trans-vitamin A acid ethylamide derivative is prepared through reaction between trans-vitamin A acid powder, phenol and phosphorus trichloride, stirring in nitrogen gas, extracting by ether, chromatography, and mass spectroscopy. It can regulate the fucosyltransferase and suppress liver cancer cell with lower poison, so it can be used to preparing antineoplastics.

The invention provides an all-trans retinoic acid quasicrystal and a liposome preparation and a preparation method thereof. An internal aqueous phase of all-trans retinoic acid liposome contains a quasicrystal structure (shown as a formula (I)) of all-trans retinoic acid-calcium with the hot melting temperature of 70-80 DEG C. By the preparation method, heating is not required, and the release stability of a medicine can be improved by prolonging the medicine loading time, so that the medicine loading amount of the medicine can be increased. Therefore, a basis is provided for use of all-transretinoic acid.

The invention discloses a vitamin A acyl cytosine arabinoside conjugate with amphipathic and a pharmacome formed by the conjugate. The invention also discloses preparation methods and the application as the antitumor agent of the conjugate and the pharmacome. The invention enables RA and cytosine arabinoside 4'-amido to be coupled so as to obtain the vitamin A acyl cytosine arabinoside conjugate with amphipathic, and the conjugate has the characteristic of self assembly of the pharmacome, thereby not only protecting the cytosine arabinoside 4'-amido from devitalizing, but also enabling the conjugate and prepared pharmacome to have the tumor targeting ability. The invention respectively takes human leukaemia cells HL-60 and S180 ascites carcinoma mousse to value the antineoplastic activity of a compound of formula I and the pharmacome prepared by the compound in vivo and in vitro, and test results show that the compound of formula I and the pharmacome thereof have excellent antineoplastic activity.

The present invention provides the use of all-trans retinoic acid for the production of a pharmaceutical composition for the treatment of acute myeloid leukemia, which use is characterized in that the patients are selected from the group of non-M3 acute myeloid leukemia patients according to a physiologic concentration, e.g. a level of MN1 below a certain critical level analysed in total blood cells, preferably analysed in bone marrow cells. The critical level of MN1 can be determined according to known methods, e.g. by specific determination of the presence of MN1, e.g. using specific anti-MN1 antibody, e.g. in an ELISA or in another immuno specific assay. Preferably, the level of MN1 is determined at its transcription level, e.g. as the concentration of mRNA encoding MN1.

The invention discloses an ethylenediamine cationic albumin antitumor nanoparticle as well as a preparation method and application of the ethylenediamine cationic albumin antitumor nanoparticle. The albumin nanometer preparation is prepared by optimally using all-trans-retinoic acid (ATRA) as an anti-tumor active substance, taking ethylenediamine cationic albumin as a drug carrier, adding a dispersant and a solvent and using an albumin-binding nanoparticle technology, and the average particle size of the albumin nanometer preparation is less than 220 nm. The preparation method of the ethylenediamine cationic albumin antitumor nanoparticle comprises the following steps: dissolving the dispersant in water to prepare a water phase, dissolving ATRA in the solvent to prepare an oil phase, mixing the water phase and the oil phase, carrying out high-speed shearing, homogenizing, then evaporating through the solvent, and performing freeze-drying to obtain the albumin nanometer preparation. Byadopting the ethylenediamine cationic albumin antitumor nanoparticle, the nanometer particle size of albumin is reduced to the nanometer level to solve the problem of solubility, therefore, the surface of human albumin has positive charges to increase the adsorption between the human albumin and tumor cells of which the surfaces have negative charges, strengthen targeting of the ethylenediamine cationic albumin antitumor nanoparticle, reduce adverse reactions, improve the curative effect and enhance the applicability of clinical use.

The invention discloses a method and culture media for inducing osteogenic differentiation of an induced pluripotent stem cell of a mouse. The method provided by the invention comprises the steps of inoculating the pluripotent stem cell of the mouse into a differentiation culture medium I to form an embryoid body with enriched mesenchymal cells, then separating the embryoid body and culturing in a differentiation culture medium II to obtain an osteoblast, wherein the differentiation culture medium I disclosed by the invention is formed by adding all-transretinoic acid and basic fibroblast growth factor on the basis of a fibroblast culture medium, and the differentiation culture medium II is formed by reducing the D-glucose content and adding BMP4 or BMP7 on the basis of an osteoblast culture medium. The method and the culture media provided by the invention can significantly promote the osteogenic differentiation of the pluripotent stem cell of the mouse, have the characteristics of short cycle, high differentiation rate, stable effect and the like, and have broad application prospect and practical value.

The application of the invention discloses an application of all-trans retinoic acid to mesenchymal stem cell polarization regulation. The application of all-trans retinoic acid to mesenchymal stem cell polarization regulation specially comprises the application of the all-trans retinoic acid to restraining of polarization of mesenchymal stem cells to osteoblasts and adipocyte. The application research confirms that the all-trans retinoic acid can restrain the polarization of mesenchymal stem cells to the osteoblast and the polarization. The application provides a new function application of the all-trans retinoic acid based on the application, the polarization regulation of the mesenchymal stem cells is researched, and polarization potential of the mesenchymal stem cells is adjusted and controlled directionally. The invention provides a new tool and an adjusting means.